Tag: MSI-H CRC treatment

Home / MSI-H CRC treatment

Categories

Nivolumab with ipilimumab is approved by the USFDA for unresectable or metastatic MSI-H or dMMR colorectal cancer

On April 8, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) and ipilimumab (Yervoy, Bristol Myers Squibb Company) for adults and children 12 years and ...
msi-h-crc-treatment

Scan the code